Atrial Fibrillation Clinical Trials

Find Atrial Fibrillation Clinical Trials Near You

Early Feasibility Study of the Append System for Left Atrial Appendage (LAA) Elimination by Invagination and Ligation

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This early feasibility study is intended to evaluate the safety and feasibility of the Append System for eliminating the left atrial appendage (LAA) through a transcatheter procedure that invaginates and ligates the LAA tissue.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male or non-pregnant female aged ≥18 years

• Documented non-valvular AF (paroxysmal, persistent, permanent or non-rheumatic valve-related AF)

• The subject has a calculated CHA2DS2-VASc score of 2 or greater for males or 3 or greater for females.

• The subject is eligible for the defined protocol medication regimen of anticoagulation and antiplatelet therapy following Append procedure.

• The patient is deemed appropriate for LAA ligation by the screening committee and the investigator.

• The patient has been informed of the nature of the study, agrees to its provisions \& follow-up evaluations, and has provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).

Locations
United States
Arkansas
Arrhythmia Research Group
RECRUITING
Jonesboro
California
Cedars-Sinai Medical Center
RECRUITING
Los Angeles
New York
Icahn School of Medicine at Mount Sinai
RECRUITING
New York
Contact Information
Primary
Liz Zinger, MSc
liz.zinger@appendmedical.com
+972-50-2071741
Time Frame
Start Date: 2026-04-29
Estimated Completion Date: 2033-03
Participants
Target number of participants: 15
Treatments
Experimental: Append System
Elimination of the left atrial appendage (LAA) using the Append System through a transcatheter procedure that invaginates and ligates the LAA tissue.
Related Therapeutic Areas
Sponsors
Leads: Append Medical Ltd.

This content was sourced from clinicaltrials.gov